News
ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback